The peroxisome: still a mysterious organelle
- First Online:
- Cite this article as:
- Schrader, M. & Fahimi, H.D. Histochem Cell Biol (2008) 129: 421. doi:10.1007/s00418-008-0396-9
- 1.7k Downloads
More than half a century of research on peroxisomes has revealed unique features of this ubiquitous subcellular organelle, which have often been in disagreement with existing dogmas in cell biology. About 50 peroxisomal enzymes have so far been identified, which contribute to several crucial metabolic processes such as β-oxidation of fatty acids, biosynthesis of ether phospholipids and metabolism of reactive oxygen species, and render peroxisomes indispensable for human health and development. It became obvious that peroxisomes are highly dynamic organelles that rapidly assemble, multiply and degrade in response to metabolic needs. However, many aspects of peroxisome biology are still mysterious. This review addresses recent exciting discoveries on the biogenesis, formation and degradation of peroxisomes, on peroxisomal dynamics and division, as well as on the interaction and cross talk of peroxisomes with other subcellular compartments. Furthermore, recent advances on the role of peroxisomes in medicine and in the identification of novel peroxisomal proteins are discussed.
KeywordsPeroxisomesMitochondriaOrganelle dynamicsBiogenesisOrganelle cross talkDynaminDiseasePexophagyFatty liver diseaseNeuroinflammation
Central nervous system
Fatty liver disease
Peroxisome biogenesis disorder
Peroxisomal membrane protein
Peroxisome proliferator activated receptor
Peroxisomal targeting signal
Reactive oxygen species
Very-long-chain fatty acids
Introduction: early milestones in peroxisome research
Disorders related to peroxisomes
Peroxisome biogenesis disorders
Zellweger syndrome (ZS) (neonatal hypotonia, craniofacial dysmorphy, hepatomegaly, renal cysts, adrenal atrophy, neurological abnormalities, such as dys- or demyelination and neuronal migration defects)
Prenatal, lethal within 1 year of age
Different PEX genes
Neonatal ALD (NALD)
1 year, lethal between 1 and 5 years of age
Different PEX genes
Infantile Refsum’s disease (IRD)
<1 year, lethal after 10–30 years of age; older patients are known
Different PEX genes
Rhizomelic chondrodysplasia punctata type 1 (RCDP type 1)
Prenatal, lethal within 1 year or the first decade; older patients are known
PTS2 matrix protein import
Single enzyme deficiencies
Enzyme and pathway affected
X-linked adrenoleukodystrophy (X-ALD) (accumulation of VLCFA, progressive demyelination/neurodegeneration in the CNS, adrenal insufficiency) “Lorenzos Oil”
3–10 years for childhood ALD, 20–40 years for adult AMN, lethal
ALDP, β-oxidation of VLCFA
Contiguous ABCD1/DX1357E deletion syndrome
ABC transporters, β-oxidation
Pseudo-neonatal ALD (acyl-CoA oxidase deficiency)
Prenatal, lethal within the first decade
d-bifunctional protein deficiency/multifunctional protein 2 deficiency
Adult-onset sensory motor neuropathy (α-methylacyl-CoA racemase deficiency)
Childhood and adult
AMACR, β-oxidation of branched chain fatty acids, including pristanic acid and bile acid intermediates; β-oxidation of VLCFA is normal
Refsum’s disease (phytanol-CoA hydroxylase deficiency)
Rhizomelic chondrodysplasia punctata type 2 (DHAPAT deficiency)
DHAPAT, ether phospho-lipid synthesis
Rhizomelic chondrodysplasia punctata type 3 (alkyl-DHAP synthase deficiency)
Sterol carrier protein X deficiency
SCPx β-oxidation of branched chain fatty acids only
Hyperoxaluria type 1 (alanine glyoxylate aminotransferase deficiency)
<5 years, lethal
AGT, glyoxylate detoxification
Potential other single enzyme deficiencies
Enzyme and pathway affected
Mental retardation X-linked 63, MRX63
Long-chain acyl-CoA synthetase 4, fatty acid activation
Malonic aciduria (MCD localizes to mitochondria, the cytosol and peroxisomes)
Early childhood (5 years)
Malonyl-CoA decarboxylase, fatty acid oxidation, but no peroxisomal abnormalities detected so far
At birth or soon after
Aldehyde dehydrogenase, phytanic acid metabolism/microsomal detoxification system
Glutaryl-CoA oxidase deficiency (glutaric aciduria type 3)
Amyotrophic lateral sclerosis (ALS1)
Variable (19–46 years)
Cu/Zn-superoxide dismutase 1
Xanthinuria (XDH localizes to peroxisomes and the cytosol)
Childhood (1–20 years)
Xanthine dehydrogenase, purine metabolism
Mulibrey nanism (muscle–liver–brain–eye nanism)
TRIM domain-dependent E3 ubiquitin ligase, unknown
Glomerulosclerosis (there is evidence that Mpv17p is mitochondrial and not peroxisomal; Spinazzola et al. 2006)
Only in mice
Mpv17 protein, PXMP 2/4 family proteins
Combined mitochondrial peroxisomal deficiencies
Enzyme and pathway affected
DLP1 deficiency (Waterham et al. 2007)
Dynamin-like GTPase, Fission defect of both mitochondria and peroxisomes
Metabolic functions of peroxisomes
Peroxide metabolism (catalase and H2O2-generating oxidases), ROS/NOS metabolism
Lipid biosynthesis (ether phospholipids/plasmalogens, bile acids, cholesterol and dolichol, fatty acid elongation)
Fatty acid β-oxidation (very-long-chain fatty acids, dicarboxylic acids, branched chain fatty acids, unsaturated fatty acids, arachidonic acid metabolism, and xenobiotic compounds)
Fatty acid α-oxidation (phytanic acid, xenobiotic compounds)
Long/very-long fatty acid activation
Regulation of acyl-CoA/CoA ratio
Protein/amino acid metabolism (biosynthesis of cysteine and sulfur assimilation, d-amino acid degradation, l-lysine metabolism, degradation of polyamines, proteases, transaminases)
Catabolism of purines
Glyoxylate and dicarboxylate metabolism
Hexose monophosphate pathway
Nicotinate and nicotinamide metabolism
The biogenesis of peroxisomes
Protein import into peroxisomes: the mysterious membrane pore
Peroxisomes do not contain DNA or protein translation machinery, and all their proteins are encoded by nuclear genes. Majority of the peroxisomal proteins are synthesized on free polyribosomes in the cytoplasm and are imported post-translationally (Lazarow and Fujiki 1985) (Fig. 3). A major breakthrough in the elucidation of the mechanism of protein import into peroxisomes was the identification of the first peroxisomal targeting signal (PTS1) at the C-terminus of luciferase of the firefly Photinus pyralis (Keller et al. 1987; Gould et al. 1987). Luciferase actually localizes to peroxisomes in cells of the lantern organ of the firefly where it catalyzes the light-producing bioluminescent reaction. Today, we know that majority of the peroxisomal matrix proteins contain a C-terminal PTS1, and very few an N-terminal PTS2. It also became clear that the import into peroxisomes is a unique process, which differs substantially from the import mechanisms into the ER, mitochondria or chloroplasts. The peroxisomes import fully folded, co-factor bound and even oligomeric proteins by shuttling receptors (Leon et al. 2006). The PTS1- or PTS2-containing matrix proteins are recognized by soluble receptors (PTS1 by Pex5p, a tetra-tricopeptide repeat (TPR) domain protein, PTS2 by Pex7p, a WD40 domain protein, and its coreceptors) in the cytosol, which guide them to a docking site at the peroxisomal membrane (Fig. 3). After translocation of the receptor–cargo complex to the luminal side of the peroxisomal membrane, the cargo is released and the receptors shuttle back to the cytosol. Whereas the components of the import machinery (the importomer complex; composed of the docking and RING subcomplexes which in yeast are bridged by Pex8p or Pex3p) (Fig. 3) and their interactions have been quite well studied (Rayapuram and Subramani 2006; Platta and Erdmann 2007b), the mechanism of translocation of folded proteins across the membrane and the cargo release still remain mysterious (Gould and Collins 2002). A stable import channel or membrane pore, like in the nucleus, is missing in the peroxisomal membrane. As an alternative to a pore, a pinocytosis-like mechanism has also been proposed (McNew and Goodman 1996). Recently, the existence of a “transient pore” has been postulated, which might be dynamically formed by the import receptors themselves (Erdmann and Schliebs 2005). In this respect, it is also noteworthy that very little is known about the membrane channels and transporters of peroxisomes, which are involved in membrane permeability and solute transfer of metabolites (Antonenkov and Hiltunen 2006; Visser et al. 2007).
It has also been shown that Pex5p can be ubiquitinated (Erdmann and Schliebs 2005; Kragt et al. 2005b; Thoms and Erdmann 2006). Monoubiquitination of Pex5p appears to be a prerequisite for its dislocation from the peroxisomal membrane, and depends on the E2 enzyme Pex4p (Platta and Erdmann 2007a; Carvalho et al. 2007). Its function has been a mystery for over a decade; however, respective E3 enzymes are still elusive (the RING finger proteins Pex2p, Pex10p and Pex12p might be good candidates for the missing ubiquitin ligases). The membrane detachment/recycling of Pex5p is ATP dependent (but not the binding and translocation of Pex5p itself), and depends on AAA-ATPases Pex1p and Pex6p (Fig. 3). Polyubiquitination of Pex5p is believed to be part of a quality control process, which results in proteasomal degradation of dysfunctional receptor molecules (Platta and Erdmann 2007a). Noteworthy, these processes show a striking analogy to ERAD, the ER-associated degradation process (see also “Peroxisomes in silico”).
Interestingly, there is experimental evidence that manipulation of the peroxisomal import of catalase has an influence on aging. The alteration of the PTS1 of catalase to a more effective serine–lysine–leucine (SKL) sequence repolarized mitochondria and reduced cellular hydrogen peroxide levels and the number of senescent cells in a population (Terlecky et al. 2006; Koepke et al. 2007). Furthermore, targeting of catalase to mitochondria in transgenic mice has demonstrated to increase murine life span (Schriner et al. 2005).
The targeting and insertion of peroxisomal membrane proteins (PMPs) require other components than those involved in peroxisomal matrix import and is less well understood (Heiland and Erdmann 2005; Van Ael and Fransen 2006; Fujiki et al. 2006). Those PMPs, which are synthesized on free ribosomes in the cytosol, contain internal membrane targeting sequences (mPTS), which comprise a Pex19p-binding site and a membrane-anchoring sequence (either a transmembrane domain or a protein binding site) (Van Ael and Fransen 2006). Pex19p is suggested to function as a cycling receptor/chaperone, which binds the PMPs in the cytosol and is then recruited to the peroxisome by the membrane receptor Pex3p (Fujiki et al. 2006) (Fig. 3). In mammals, Pex16p is also required, which might function as a tethering factor for Pex3p, or as part of the putative membrane-insertion machinery. A loss of Pex3p, Pex16p, or Pex19p results in the absence of detectable peroxisomes/peroxisomal membranes, whereas reintroduction surprisingly leads to a de novo formation of peroxisomes from the ER (see below). Some PMPs (e.g., Pex3p and Pex16p) are supposed to be targeted indirectly to peroxisomes via the ER by an as yet unknown mechanism (see below).
Mysterious formation: growth and division, de novo formation, or both?
Since their discovery in 1954, there has been much speculation about the formation of peroxisomes. It was suggested that peroxisomes were precursors of mitochondria (Bernhard and Rouiller 1956), that they could arise from the Golgi complex (Rouiller and Jezequel 1963) or were specialized forms of lysosomes (Novikoff and Essner 1960). Whereas those concepts were abandoned with improvements in cytochemical methods, it was also proposed that peroxisomes formed from terminal cisternae of the ER (Novikoff and Shin 1964). However, the discovery of the synthesis of peroxisomal proteins on free polyribosomes in the cytoplasm (Goldman and Blobel 1978), their post-translational transport into peroxisomes, and the observations of interconnections between peroxisomes, led to the proposal of the “growth and division” model of peroxisome biogenesis with formation out of pre-existing organelles (Lazarow and Fujiki 1985). Recent discoveries have again challenged this classical view. The peroxins Pex3p, Pex19p and Pex16p are required to maintain the peroxisomal membrane (South and Gould 1999; Hettema et al. 2000; Heiland and Erdmann 2005), and their loss of function leads to the absence of peroxisomal membranes and thus, peroxisomes. Transexpression of Pex3, Pex19 or Pex16 and re-introduction of the missing genes has now been demonstrated to restore peroxisome formation in yeast and mammals, and lead to the postulation of a de novo synthesis of peroxisomes (Matsuzono et al. 1999; South and Gould 1999; Muntau et al. 2000; Titorenko and Rachubinski 2001; Faber et al. 2002; Geuze et al. 2003; Hoepfner et al. 2005; Kragt et al. 2005a; Haan et al. 2006; Kim et al. 2006). Pex3p and Pex19p have been observed to initially localize to the ER before maturing into import-competent peroxisomes (Hoepfner et al. 2005; Tam et al. 2005; Haan et al. 2006), indicating that the ER/nuclear envelope is the source of the newly synthesized membrane and organelle.
The physiological significance of the mechanism of de novo formation in comparison to the classical pathway of growth and division is still controversially discussed (Lazarow 2003; Kunau 2005; Haan et al. 2006; Mullen and Trelease 2006; Tabak et al. 2006). In order to investigate to what extent these pathways of peroxisome formation contribute to peroxisome numbers in yeast, Motley and Hettema (2007) have developed an elegant, fluorescence-based mating assay to follow the fate of existing and de novo-formed peroxisomes in S. cerevisiae. They provide evidence that in wild-type cells (grown on a nonfermentable carbon source) peroxisomes multiply by growth and division and do not form de novo. Only cells lacking peroxisomes as a result of a segregation defect were observed to form peroxisomes de novo out of the ER. In contrast to peroxisome fission, de novo formation was much slower and appeared to be independent of DLPs such as Dnm1p or Vps1p (Motley and Hettema 2007; Nagotu et al. 2007; Jourdain et al. 2008). In some yeasts, which possess only a few peroxisomes, de novo formation may therefore represent a rescue mechanism that becomes functional in case peroxisomes are lost (e.g., due to failure in inheritance). Several components involved in peroxisome inheritance in yeast have recently been discovered, for example the peroxisomal proteins Inp1p and Inp2p, which together with the type V myosin motor Myo2p and actin play a role in the retention and motility of peroxisomes (Fagarasanu et al. 2006, 2007) (Fig. 3).
However, there is now also firm evidence that some peroxisomal proteins are routed indirectly to peroxisomes via the ER (e.g. Pex3p) (Hoepfner et al. 2005; Tam et al. 2005; Kragt et al. 2005a; Haan et al. 2006; Kim et al. 2006; Mullen and Trelease 2006; Motley and Hettema 2007). This trafficking pathway is supposed to involve ER-derived vesicular or preperoxisomal structures, which do not require DLPs for exit from the ER (Motley and Hettema 2007; Nagotu et al. 2007), and are observed to fuse with pre-existing peroxisomes. Thus, a semi-autonomous model of peroxisome formation can be envisaged, whereby the ER supplies existing peroxisomes with essential membrane proteins (and lipids) to allow peroxisomal growth and division (Fig. 5). However, it is currently not understood how the peroxisomal proteins enter and leave the ER, how they are sorted and packaged, what the nature and composition of the ER-derived structures is, how fusion with peroxisomes is mediated, and if a retrograde, peroxisome-to-ER pathway exists (Fig. 5). Interestingly, such a retrograde transport pathway has recently been proposed in infected plant cells (McCartney et al. 2005; Mullen and Trelease 2006) and trypanosomes (Subramanya and Mensa-Wilmot 2006). Furthermore, a role of the Dsl1p secretory complex in regulating de novo synthesis of peroxisomes from the ER has been very recently proposed in S. cerevisiae (Perry and Rachubinski 2007).
Mysterious trafficking: a novel vesicular mitochondria-to-peroxisome pathway?
Besides vesicular ER-to peroxisome transport, even a transport route between mitochondria and peroxisomes might exist (Fig. 5). Neuspiel et al. (2008) have very recently identified a new outer membrane mitochondrial anchored protein ligase (MAPL) containing a RING finger domain. MAPL appeared to have a regulatory function in controlling mitochondrial morphology. Excitingly, MAPL was also incorporated within unique, vesicular structures, which emanated from the sides of mitochondria. These new mitochondrial-derived vesicles (MDVs) (70–100 nm in diameter) formed in a DLP1-independent manner, showed an increase in electron density around the surface, and often contained both outer and inner mitochondrial membranes, which appeared as two concentric circles. Remarkably, in live-cell experiments MAPL-YFP-positive vesicles were observed to fuse with a small subset of peroxisomes (Neuspiel et al. 2008). Furthermore, other populations of MDVs were discovered, which excluded MAPL, but contained TOM20 (which was absent form MAPL-positive MDVs). The TOM20-positive MDVs did not fuse with peroxisomes, and their fate is still under investigation. However, it might be possible that these vesicles contribute to the removal of damaged, misfolded, or mistargeted proteins from the mitochondria/mitochondrial membranes, and route them to the lysosomal/autophagic degradation pathway (Fig. 5). The physiological function of the new vesicular mitochondria-to-peroxisome transport pathway is also still mysterious. MAPL appears to be present at low levels in only a subpopulation of peroxisomes, and is not required for MDV formation at the mitochondria or targeting to peroxisomes. Silencing or overexpression of MAPL was not observed to change peroxisomal morphology, and thus, it might not play a role in peroxisomal growth and division (in contrast to its function on mitochondria). Peroxisomes and mitochondria are metabolically linked organelles, which cross talk and cooperate, and even share components of their division machinery (Schrader 2006; Schrader and Yoon 2007) (Figs. 1, 4). The MAPL-positive MDVs might therefore function in the transport of metabolites, lipids, or proteins to a peroxisome subpopulation. Interestingly, a dual localization to both peroxisomes and mitochondria has been observed for mitochondrial enzymes and some mitochondrial membrane proteins (e.g., Fis1p, Mosc2, and ATAD1, a member of the AAA-superfamily of ATPases) (Koch et al. 2005; Wiese et al. 2007) (see “Peroxisomes and mass spectrometry”). However, Fis1p and the other proteins are found in the vast majority of peroxisomes (distinct from MAPL), and are presumably imported directly from the cytosol. An alternative function of the peroxisome-targeted MDVs might be the retrieval of peroxisomal (membrane) proteins, which have been mistargeted to mitochondria. Mistargeting of peroxisomal membrane proteins to mitochondria is often observed under different experimental conditions, for example when peroxisomal membrane insertion is affected (Sacksteder et al. 2000; Soukupova et al. 1999), and might be due to some overlap in the targeting information that is also recognized by the mitochondrial import machinery (Van Ael and Fransen 2006; Subramani 1998). Another interesting issue is the fusion event of a double-membrane-bound MDV with a single-membrane-bound peroxisome (Neuspiel et al. 2008). Such a fusion would likely result in the release of a single-membrane-bound vesicle (the former inner mitochondrial membrane) into the lumen of the peroxisome. Internal peroxisomal membrane structures have been described in yeast cells and in mammalian tissue (McNew and Goodman 1996), and very recently after deletion of the peroxisomal lipase Lpx1p in S. cerevisiae (Thoms et al. 2008). It will be very interesting to elucidate the fate of the putative vesicle remnant, and to identify the components of the putative MDV-peroxisome fusion machinery.
It is intriguing to speculate that peroxisomes themselves—like mitochondria—might be able to emenate vesicles from their membranes (which would then be PDVs, peroxisome-derived-vesicles) (Fig. 5). Budding events at the peroxisomal membrane have been occasionally observed (Jedd and Chua 2002). Furthermore, ADP-ribosylation factor (ARF) and coatomer have been localized to peroxisomes (Passreiter et al. 1998; Lay et al. 2005). Efforts to link ARF and coatomer recruitment to (ER-derived) peroxisome formation or growth and division have so far been inconclusive or are difficult to interpret (Lay et al. 2006). It might actually be possible that these components play only a minor, if any, role in peroxisome formation, but are instead involved in the generation of PDVs, which might either deliver metabolites, lipids, or (mistargeted) proteins to mitochondria (or to other subcellular compartments, e.g., to the ER; see “Mysterious formation: growth and division, de novo formation, or both?”), or might be involved in the removal of damaged (e.g., by peroxisomal ROS production), misfolded, or mistargeted (mitochondrial?) proteins from the peroxisomal membranes, and route them to the lysosomal/autophagic degradation pathway (Fig. 5). As the peroxisome appears to be connected to transport pathways coming from the ER and presumably also from mitochondria, there will certainly be some degree of mistargeting. Therefore, mechanisms must exist, which assist the peroxisome in getting rid of potentially mistargeted proteins, especially those in the peroxisomal membrane, which are not readily accessible to peroxisomal enzymes/proteases (e.g., membrane proteins mainly exposed to the cytoplasm). Besides vesicle formation, these mechanisms might also include polyubiquitination (Platta and Erdmann 2007a) or autophagy/pexophagy of the whole organelle (Sakai et al. 2006) (see below).
Mysterious removal: degradation and autophagy of peroxisomes
The number of peroxisomes in cells and their enzymatic equipment is modified depending on metabolic state and the environmental requirements. A well-known characteristic of peroxisomes is their inducibility by divergent chemicals and drugs which is mediated by the transcription factors referred to as “peroxisome proliferator activated receptors” (PPARs) (Issemann and Green 1990). Upon withdrawal of treatment, the peroxisome proliferation is reversed and the excess particles are removed by autophagy (Yokota 1993) (Fig. 2e), which in the case of yeast cells is also referred to as pexophagy (Sakai et al. 2006). Autophagy is a process regulated by ATG genes, which determine the sequestration and degradation of cell organelles and other cellular components within lysosomes or vacuoles. Two distinct mechanisms of sequestration by autophagy have been described: macroautophagy and microautophagy. Whereas in macroautophagy the cell components (e.g., peroxisomes) are first sequestered within autophagosomes, which in turn fuse with lysosomes/vacuoles, in microautophagy membrane events occur on the surface of the vacuole/lysosome which then engulf the cell components to be digested resulting in the formation of microautohagic bodies (Sakai et al. 1998a). From the numerous ATG genes (Klionsky et al. 2003) involved in general cellular autophagy, many have also been identified to participate in pexophagy (Schroder et al. 2007). On the other hand, much less is known about the peroxisomal components, which are involved in this process. In the yeast Hansenula polymorpha two peroxisomal membrane proteins, HpPex3p (Bellu et al. 2002) and HpPex14p (Bellu et al. 2001), appear to be important in the process of macropexophagy. In yeasts lacking HpPex14p, degradation of peroxisomal membranes is defective and it is suggested that the highly conserved N-terminal region of HpPex14p is necessary for macropexophagy. Since Pex14p has also been known to be a translocon and is involved in the formation of peroxisomes (Fig. 3), it is the only Pex protein that participates both in peroxisome formation and degradation (Zutphen et al. 2008). The yeast models Pichia pastoris and H. polymorpha have extensively been used for the analysis of molecular events and the morphological steps of pexophagy, and there are excellent recent reviews on this subject (e.g., Dunn et al. 2005; Sakai et al. 1998b, 2006; Platta and Erdmann 2007a).
In mammalian hepatocytes, the degradation of peroxisomes by autophagy was noted quite early by electron microscopic studies in rodents treated with hypolipidemic drugs (Leighton et al. 1975; Moody and Reddy 1976; Staubli et al. 1977) (Fig. 2e). Although the morphological aspects and the participation of lysosomes in this process were well characterized (Yokota 2003), its molecular aspects remained quite mysterious compared to yeast cells. Recently, Iwata et al. (2006) reported that in Atg7-deficient mice (lacking the essential gene for autophagy), the excess peroxisomes induced by phthalate ester could not be degraded within 1 week after discontinuation of the treatment. Moreover, the Atg7-deficient hepatocytes lacked the autophagosomes containing sequestered peroxisomes, thus confirming the role of autophagy in degradation of excess peroxisomes. Further studies are required to analyse the role of other genes and their products in autophagy in mammalian systems and the search has just started (Monastyrska and Klionsky 2006).
In addition to the autophagic degradation of excess peroxisomes discussed above, another unique aspect of turnover of this organelle deserves to be mentioned, namely, the possible role of 15-lipoxygenase in selective destruction of peroxisomal membranes in normal untreated animals. In reticulocytes, 15-lipoxygenase has been shown to bind selectively to the membranes of organelles and induce the diffusion of their contents (van Leyen et al. 1998). The importance of this process for the degradation of cell organelles in differentiating lens fibres (Bassnett and Mataic 1997) and in maturation of reticulocytes has been suggested (Schewe et al. 1975). This notion has been confirmed recently in Atg5−/− mice which show normal organelle degradation in lens fibres and erythroid cells inspite of inability to form autophagic vacuoles (Matsui et al. 2006). The presence of 15-lipoxygenase in the membranes of normal rat hepatocyte peroxisomes was demonstrated recently, and it was suggested that, similar to maturing reticulocytes and lens fibres, it could also be involved in the degradation of peroxisome membranes (Yokota et al. 2001). This notion is supported by the observation that 15-lipoxygenase was detected in only some but not all peroxisomes and that its presence correlated with the diffusion of catalase from some but not all peroxisomes in aldehyde fixed sections of rat liver. The latter finding was reported almost 30 years before and was contributed to the heterogeneous stability of peroxisome membranes (Fahimi 1974). Since the disruption of peroxisome membranes and the diffusion of catalase were both prevented by inhibitors of 15-lipoxygenase such as propyl gallate and esculetin, it was suggested that 15-lipoxygenase could participate in physiological degradation and turnover of peroxisomes in normal untreated animals, contrasting the role of autophagy in degradation of excess peroxisomes induced by treatment with chemicals and drugs (Yokota et al. 2001).
Mysterious protection: some recent observations on the relevance of peroxisomes in medicine
There are by now more than two dozens inborn metabolic disorders due to various dysfunctions or absence of peroxisomes and that number is growing (Schluter et al. 2007). Table 1 summarizes those disease conditions with the age of the onset, the basic metabolic defect and the genes involved. In addition to those genetic peroxisomal disorders, which have been addressed in recent excellent reviews (Weller et al. 2003; Wanders and Waterham 2005, 2006a; Faust et al. 2005; Steinberg et al. 2006), there is also increasing evidence that peroxisomes may be affected in some medical conditions associated with disorders of the lipid metabolism. Since peroxisomes and their proteins can be induced by a variety of drugs and chemicals, generally referred to as PPAR-agonists, there are emerging new possibilities for therapy of those conditions. Two such disorders are briefly discussed here: fatty liver disease and neuroinflammation.
Peroxisomes in fatty liver disease
The fatty liver disease (FLD) represents an excess accumulation of triglycerides in hepatic parenchymal cells. Whereas in the past excess ethanol consumption accounted for most cases, which were called alcoholic FLD (AFLD), in the last two decades, the non-alcoholic FLD (NAFLD), particularly in association with obesity, has emerged as the most common chronic liver condition in the western world (Adams et al. 2005). NAFLD is now present in 17–33% of the population in the United States, but has a world-wide distribution, and parallels the frequency of central adiposity, obesity, insulin resistance, metabolic syndrome and type 2 diabetes (Farrell and Larter 2006). In almost one-third of NAFLD cases, there is an associated steatohepatitis (NASH), which progresses to hepatic fibrosis and upon chronicity to liver cirrhosis. Many cases of the so-called cryptogenic liver cirrhosis are likely end-stage NASH (Neuschwander-Tetri and Caldwell 2003). Although insulin resistance is the underlying problem, in the pathogenesis of FLD both excess energy consumption as well as defective energy combustion contribute to a sequence of events which begins with hepatic steatosis and ends in liver cirrhosis and cancer (Reddy and Rao 2006). Whereas hepatic steatosis is considered to be innocuous and reversible, the progression to steatohepatitis is influenced by the severity and persistence of the causative agent and additional factors. According to the “two-hit” hypothesis, secondary insults that may severely damage the steatotic liver include reactive oxygen species, endotoxin, tumor necrosis factor-alpha (TNFα) and other cytokines (Day and James 1998). In this respect, it should be noted that inflammatory cytokines such as TNFα have been shown to suppress the hepatic peroxisomal catalase and the lipid β-oxidation enzymes, as well as the transcription factor PPARα, at both protein and mRNA levels (Beier et al. 1992, 1997). The reduction of the fatty acid β-oxidation enzymes in peroxisomes could contribute to the lipid accumulation in hepatocytes and to the severity of steatohepatitis. Indeed, mice lacking the peroxisomal acyl-CoA oxidase gene develop severe steatohepatitis, lipogranulomas and hepatocellular carcinomas (Fan et al. 1998). Some of the features of those AOX−/− mice resemble the spectrum of obesity associated human liver alterations justifying further detailed studies of peroxisomes in patients with morbid obesity and type 2 diabetes.
From the PPAR subfamily of nuclear transcription factors (Michalik et al. 2006), the PPARα functions mainly as a lipid sensor in the liver responding to the influx of fatty acids by up-regulation of the transcription of genes involved in β-oxidation of fatty acids in peroxisomes and mitochondria, as well as the microsomal ω-oxidation system. PPARα−/− mice cannot respond to increased fatty acid influx and develop severe hepatic steatosis (Hashimoto et al. 2000). Such PPARα–/− mice also develop severe steatohepatitis after feeding with a choline and methionine deficient diet (Kashireddy and Rao 2004). Interestingly, both agonists of PPARα and PPARδ have been found to improve the hepatic steatosis and prevent the inflammation associated with steatohepatitis induced by choline-methionine deficient diet in mice (Nagasawa et al. 2006). More importantly, in rats with severe steatohepatitis and liver fibrosis induced by a choline-methionine deficient diet, administration of PPARα agonists prevents not only the development of steatohepatitis but also reverses the fibrotic process in the liver (Rao et al. 2002). Thus, it seems that induction of fatty acid oxidation enzymes by activation of PPARα and PPARδ can prevent the development of hepatic steatosis. Indeed, in clinical studies, the PPARγ agonists rosiglitazone (Neuschwander-Tetri et al. 2003) and pioglitazone (Promrat et al. 2004) have been tried and found to improve significantly all histological and biochemical features of non-alcoholic steatohepatitis. This has also been proven in a placebo-controlled trial with pioglitazone justifying further long-term studies (Belfort et al. 2006). Thus, PPAR-agonists such as fibrates or thiazolidinediones offer the potential for treatment of not only the hepatic complications but also the underlying disease process of metabolic syndrome and type 2 diabetes with dyslipidaemia (Plutzky 2007; Staels 2007).
Peroxisomes and neuroinflammatory diseases
The severe structural and functional abnormalities of the central nervous system (CNS) seen in patients with peroxisome biogenesis disorders (PBDs) (Evrard et al. 1978; Powers et al. 1985) (Table 1) demonstrate the important role of peroxisomes in normal development and function of the brain. This is also confirmed in brain specific gene-knock out mouse models of PEX5 (Janssen et al. 2003) and PEX2 (Faust 2003), which exhibit neuronal migration defects and abnormalities in cerebellar histogenesis, respectively. Recently, in a mouse model of selective knock out of PEX5 in oligodendrocytes, the central role of peroxisomes in the myelination process was demonstrated (Kassmann et al. 2007). Although the mutant mice appeared normal at birth, within a few months they developed ataxia, tremor and died prematurely with widespread evidence of axonal degeneration and progressive subcortical demyelination. Moreover, severe inflammation accompanied the axonal degeneration with infiltration of B and CD8+ T cells in cerebral lesions resembling closely the neuroinflammatory lesions associated with human demyelinating disorders, particularly the multiple sclerosis.
Thus, it seems that peroxisomes in oligodendrocytes have a neuroprotective function preventing not only the axonal degeneration but also the associated process of neuroinflammation. The anti-inflammatory function of peroxisomes and the regulatory role of PPAR-activators in this process were discovered more than a decade ago (Devchand et al. 1996). Both, PPARα and PPARγ, are expressed on T cells, and their respective agonists inhibit the secretion of interleukin-2 and the proliferation of T cells (Cunard et al. 2002; Marx et al. 2002). Moreover, PPAR-agonists have been found to inhibit the progression of a variety of inflammatory diseases in experimental animals such as adjuvant arthritis in rats (Kawahito et al. 2000), inflammatory bowel disease (Su et al. 1999) and atherosclerosis in mice (Li et al. 2000). Experimental autoimmune encephalomyelitis (EAE) is an autoimmune disorder in mice characterized by inflammation of the CNS and severe demyelination which are the typical features of multiple sclerosis in humans and both PPARγ and PPARα agonists have been shown to exert therapeutic effects in the mouse model (Niino et al. 2001; Diab et al. 2002; Xu et al. 2007). Moreover, in a report of a single patient with severe multiple sclerosis, pioglitazone, a PPARγ activator, was found to substantially improve the patients condition (Pershadsingh et al. 2004). Those observations have now stimulated the call for large-scale clinical trials of PPAR-agonists for therapy of multiple sclerosis (Racke et al. 2006; Niino 2007). Since an inflammatory process in the brain is also observed in other severe conditions affecting the CNS such as Alzheimer’s and Parkinson’s disease, PPAR-agonists have also been tried (Landreth 2007; Dehmer et al. 2004) with promising results, thus justifying future trials of those drugs in various neurological disorders associated with neuroinflammation. It is of interest that not all effects of those receptor-agonists are mediated via the activation of PPAR, since some therapeutic effects are also observed with gemfibrozil, a PPARα agonist, in PPARα−/− mice with autoimmune encephalomyelitis (Dasgupta et al. 2007) suggesting receptor independent mechanisms of action. This is, however, mostly new territory where therapeutic benefits of those drugs remain to be discovered. The exact knowledge of the structure and function of peroxisomes and their heterogeneity in the CNS, as reported recently (Ahlemeyer et al. 2007) is a prerequisite for such future studies.
Mysterious players: identifying novel peroxisomal proteins
Peroxisomes in silico
The rapid advances in genome sequencing allow computational approaches (comparative genomics) to predict peroxisomal proteins. These in silico analyses take advantage of the conserved targeting sequences in peroxisomal proteins (i.e. PTS1, PTS2, see “Introduction” and Fig. 3). PTS domain-based comparisons across genomes from yeast to humans and plants have been performed, predicting large numbers of putative peroxisomal proteins (Emanuelsson et al. 2003; Kurochkin et al. 2005; Kamada et al. 2003; Reumann et al. 2004, database AraPerox: http://www.araperox.uni-goettingen.de/; Hawkins et al. 2007). Some of the predictions have already been confirmed experimentally, others still await validation. There are, however, limitations, because many proteins of peroxisomes cannot currently be predicted from genome sequences. These include peripheral and integral membrane proteins, proteins that are imported in a piggy-back fashion, or matrix proteins with internal PTS1-like peptides. On the other hand, predicted PTSs can be masked by protein conformation, multimer formation, or posttranslational regulatory mechanisms.
Recently, computational approaches on the basis of proteomes and sequenced genomes of different organisms have been used to investigate the evolutionary origin of peroxisomes (Schluter et al. 2006; Gabaldon et al. 2006; Schluter et al. 2007, peroxisome database: http://www.peroxisomedb.org/). The peroxisomal proteins Pex3p, Pex19p, Pex10p, and Pex12p have been identified as markers for unequivocal in silico peroxisome detection (Schluter et al. 2006). The Apicomplexa phylum (containing for example, Plasmodium falciparum, Cryptosporidium parvu) has been detected as the first group of organisms devoid of peroxisomes in the presence of mitochondria. The absence of peroxisomes had so far only been documented in amitochondriate parasites, such as Encephalitozoon cuniculi, Girardia lamblia, or Entamoeba histolytica. Interestingly, a high degree of similarity among membrane proteins and between components of the matrix import machinery and the endoplasmic reticulum/proteasome degradation system has been observed (see “Mysterious formation: growth and division, de novo formation, or both?”) (Schluter et al. 2006; Gabaldon et al. 2006). Most of the conserved peroxisome biogenesis and maintenance proteins are apparently eukaryotic innovations with no prokaryotic counterpart. This is consistent with findings that report an ER-dependent formation of peroxisomes (see “Mysterious formation: growth and division, de novo formation, or both?”) (Tabak et al. 2006), and indicates that peroxisomes do not have an endosymbiotic origin. In contrast, many peroxisomal matrix enzymes were found to have prokaryotic homologues. These might have been recruited individually from pools existing within the primitive eukaryote (e.g., from mitochondria), but an en bloc recruitment of this coherent collection of enzymes can also be envisaged (de Duve 2007). It is still an open (but interesting, and hotly debated) question, when the peroxisomes first appeared in the evolution of the eukaryotic cell, and if they might have been present before the adoption of mitochondria (Cavalier-Smith 1997).
Peroxisomes and mass spectrometry
The recent technical advances in two-dimensional gel electrophoresis (2D-GEP), liquid chromatography (LC), as well as mass spectrometrical (MS) peptide identification and quantification laid the foundation for progress in organellar proteome studies, and have also been exploited to unravel the peroxisomal proteome. These studies depend not only on the availability of complete genome information or large EST collections of the species of interest for protein identification but also on the purity of the isolated organelle fraction. Due to the fragile nature of peroxisomes, the isolation of intact peroxisomes in high purity and sufficient quantity is difficult. However, sophisticated protocols have been developed for the isolation of mammalian peroxisomes, for fungi and yeast, as well as for plant peroxisomes (e.g., Völkl et al. 1996, 1999; Luers et al. 1998; Weber et al. 2004; Distel and Kragt 2006; Reumann et al. 2007).
One-dimensional (1D) and 2D-GEP of peroxisomes from rat liver followed by LC/tandem MS or MS resulted in the identification of more than 50 known constituents as well as novel peroxisomal proteins, among them a new isoform of Lon protease (one of the first peroxisomal proteases discovered) (Kikuchi et al. 2004), microsomal gluthatione-S-transferase (Islinger et al. 2006), as well as the known microsomal proteins aldehyde dehydrogense, cytochrome b5 and its corresponding reductase (Kikuchi et al. 2004; Islinger et al. 2006; Wiese et al. 2007). An early high throughput characterization of the yeast peroxisomal membrane proteome was performed by Schafer et al. (2001) using oleate-induced cultures. In order to differentiate between proteins that are contaminants of low abundance and those that have specifically enriched in the purified peroxisome fractions, efforts have been made to study relative protein quantities. Aitchinson and coworkers introduced a relative quantitative MS-based proteomics approach (ICAT, isotope-coded affinity tagging) to determine the enrichment or depletion of proteins detected in two peroxisomal membrane fractions from S. cerevisiae that differed in their degree of purity, and revealed a role for the GTPase Rho1p in actin organization on the peroxisomal membrane (Marelli et al. 2004; Saleem et al. 2006). In another quantitative MS-based proteomics approach (iTRAQ, isobaric Tag for Relative and Absolute Quantitation) with peroxisome matrix and membrane subfractions from bezafibrate treated rats, Islinger et al. (2007) identified 134 individual proteins, including 15 new candidates, among them the new peroxisomal membrane proteins PMP52 (unknown function, related to PMP24), the iron–sulfur protein Mosc2 (MOCO sulphurase C-terminal domain containing 2 protein), and splice variants of the acyl-CoA binding protein ACBD5, as well as a trypsin-like serine protease (Tysnd1) of the peroxisomal matrix (Fig. 3). The mouse variant of this protease has been identified and characterized in detail (Kurochkin et al. 2007). Interestingly, Tysnd1 removes the leader peptide from PTS2 proteins and specifically processes PTS1 proteins involved in peroxisomal β-oxidation. Proteomic characterization of mouse kidney peroxisomes by tandem MS and protein correlation profiling has also led to the identification of 15 new peroxisomal candidates including Zadh2 (Zinc-binding alcohol dehydrogensase domain containing protein 2), Acad11 (acyl-CoA dehydrogenase family member 11), the aforementioned ACBD5, PMP52, Mosc2 (Wiese et al. 2007), as well as nudix hydrolase 19 (RP2) (Ofman et al. 2006). In addition, a quantitative proteomic comparison of mouse peroxisomes from liver and kidney has been performed (Mi et al. 2007b), as well as an age-related subproteomic analysis (Mi et al. 2007a). With the development of a purification method for leaf peroxisomes, Reumann et al. (2007) were able to perform a comprehensive proteome analysis of Arabidopsis leave peroxisomes. They identified 42 novel proteins that had previously not been assigned to plant peroxisomes revealing novel targeting peptides, metabolic pathways, and defense mechanisms (Reumann et al. 2007). All these studies have contributed to a more complete picture of the peroxisome, and clearly demonstrate that we are not looking at an isolated structure, but rather on a dynamic compartment that is linked to (and might interact with) other subcellular structures (e.g. the ER, mitochondria, chloroplasts, the cytoskeleton, lipid droplets/bodies and other peroxisomes), and even shares proteins with them (in particular with the ER and mitochondria).
Although mass spectrometry can generally be more accurate than antibody-based detection methods, a validation of the proteins predicted to be peroxisomal is often required. The peroxisomal localization of some of the identified novel proteins has been experimentally confirmed by expression studies with tagged proteins, and by antibody-based approaches such as immunofluorescence microscopy and immunoblotting (e.g. Marelli et al. 2004; Islinger et al. 2006, 2007; Wiese et al. 2007).
In addition, large-scale localization studies have been performed in which the whole genome or a subset of the organisms’ proteome was systematically tagged with GFP. The subcellular localizations of the GFP fusion proteins and their dynamics can then be addressed under live cell conditions, and several fusion proteins with peroxisomal localization have been identified by this approach (Cutler et al. 2000; Kumar et al. 2002; Huh et al. 2003; Natter et al. 2005).
Nevertheless, a lot of large-scale data are awaiting validation and contextualization. The great challenge for the future will be to provide a comprehensive and more complete picture of the relevant peroxisomal proteins, their abundance, functions, interactions and dynamic changes (Saleem et al. 2006). This can only be achieved by incorporating data from multiple sources, such as localization (see above) and interaction studies (e.g., two hybrid studies, analyses of immunoisolated protein complexes), metabolite interactions, and microarray expression analyses.
This review has highlighted recent novel discoveries in the peroxisome field. Ongoing studies on peroxisome biogenesis, formation and protein import have so far revealed unique features of peroxisomes, which have often been in disagreement with existing dogmas in cell biology. Contrary to mitochondria and ER, peroxisomal proteins can be imported in a completely folded or even oligomeric state, presumably via the formation of a transient membrane pore (Erdmann and Schliebs 2005). Recent findings also demonstrate that peroxisomes can be formed de novo from the ER or a subdomain of the ER (Hoepfner et al. 2005) in addition to growth and division of pre-existing peroxisomes (Yan et al. 2005; Schrader 2006; Fagarasanu et al. 2007). Furthermore, they appear to have an ER origin in evolutionary history (Gabaldon et al. 2006; Schluter et al. 2006). The physiological significance of the mechanism of de novo formation in comparison to the classical pathway of growth and division has again been challenged (Motley and Hettema 2007) and awaits further approval. In contrast to peroxisome division, de novo formation appears to be independent of dynamin-like proteins (Motley and Hettema 2007; Nagotu et al. 2007) and thus, the molecular machinery for de novo formation remains to be identified. Many new proteins affecting peroxisome growth, number, division, inheritance and turnover have been characterized and much has been learned about their putative function, localization, and possible interaction with other proteins. The discovery that dynamin-related proteins like Vps1, DLP1/Drp1 and DLP/Drp-receptor proteins like Fis1p are required for peroxisomal fission has opened the field for the molecular characterization of the peroxisomal division machinery (Schrader and Fahimi 2006). Interestingly, peroxisomes and mitochondria share components of their fission machinery, underlining the tight cooperation and cross talk between both organelles (Schrader 2006; Schrader and Yoon 2007). It is still an open question, how the dual targeting of these components is mediated, and if organelle-specific components exist which distinctly regulate the assembly of the division machineries on both organelles. Furthermore, the mechanism of peroxisome constriction and of membrane phospholipid transfer during growth or de novo synthesis remains to be discovered. Another important question is, if and how peroxisomal morphology and dynamics influence peroxisomal functions as well as developmental and physiological processes. An improved understanding of the signalling pathways and the PPAR-mediated mechanism of peroxisome proliferation will further stimulate the investigation of the risks and benefits of peroxisome proliferators as therapeutical agents, for example in fatty liver disease or neuroinflammatory diseases.
There is firm evidence now for a semi-autonomous model of peroxisome formation, whereby the ER supplies existing peroxisomes with essential membrane proteins to allow growth and division. It will be a great challenge for the future to elucidate this trafficking pathway, which is supposed to involve ER-derived vesicular or pre-peroxisomal structures. Surprisingly, besides vesicular ER-to peroxisome transport, even a vesicular transport route between mitochondria and peroxisomes might exist (Neuspiel et al. 2008). It will therefore be of significant interest to unravel to what extend, why and how peroxisomes interact and exchange with other subcellular compartments, and whether they are themselves involved in the formation of vesicles. It is clear now that we are not looking at an isolated structure, but rather on a dynamic compartment that is linked to other subcellular structures, interacts with them and even shares proteins. There is no doubt that peroxisomes, which are still among the more mysterious subcellular compartments in eukaryotic cells, will reveal further surprises in the near future.
We thank Ronald Wanders, Alfred Völkl, Markus Islinger, and Georg Luers for helpful suggestions, and members of the laboratories for stimulating discussions and comments on the manuscript. We apologize to those whose work has not been cited due to space limitations. Supported by the German Research Foundation (DFG) (SCHR 518/6-1) and the Portuguese Foundation for Science and Technology (FCT) (PTDC/BIA-BCM/71932/2006).